Biotechnology

Faeth Therapeutics stock analysis: a pre-revenue clinical biotech trading near its two-year high, with no debt, steep losses and a model rating of N/A.

Madrigal Pharmaceuticals stock analysis: 71% revenue growth meets a rich 24x price-to-book near two-year highs. Model signal: Hold.

IDEAYA Biosciences, Inc. stock analysis: shares sit near a two-year high while a -36.4% gross margin and 25/100 quality score drive a Sell signal.

Insmed Incorporated stock analysis: revenue up 296.1% with a 90/100 growth score, offset by a -76.9% net margin and a Hold signal from our model.

ACADIA Pharmaceuticals stock analysis: ACAD hits a 2-year high on strong profitability, but a rich EV/EBITDA multiple keeps the model at Hold.

Beam Therapeutics stock analysis: BEAM nears its 2-year high as revenue drops 94% YoY, driving the model’s signal to Sell.

Recursion Pharmaceuticals stock analysis: RXRX nears its two-year low as revenue drops 60.1% TTM and cash burn continues despite a strong balance sheet.